Ovarian Cancer
News and reporting on ovarian cancer.
Allarity Therapeutics Board Authorizes $5M Share Repurchase Program
The company said the move demonstrates the board of directors' confidence in the potential of its PARP1/2 inhibitor in ovarian cancer.
Class Action Securities Lawsuit Against Allarity Therapeutics Dismissed
Shareholders sued Allarity over alleged false statements about the prospects for approval of the firm's investigational kidney cancer therapy.
Allarity Therapeutics Advances New Protocol for Stenoparib Phase II Ovarian Cancer Trial
The firm will test additional doses and use its proprietary drug response predictor to gather data that can inform a registrational study.
Context Therapeutics Begins Phase I Trial of Bispecific Antibody in CLDN6-Positive Tumors
The firm will evaluate its CLDN6- and CD3 T-cell-engaging bispecific antibody in advanced or metastatic ovarian, endometrial, and testicular cancers.
Verastem Seeking FDA Approval for Avutometinib, Defactinib in KRAS-Mutant Ovarian Cancer
The FDA granted priority review to the company's avutometinib-defactinib application and expects to decide on approval in June 2025.